Clinical Trial Update: H3K27M-specific Immune Effector Cells Targeting DMG/DIPG [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of H3K27M-targeted immune effector cells for diffuse midline glioma and DIPG is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• Diffuse Midline Glioma

Drugs mentioned

• H3K27M-specific Immune Effector Cells

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1, Phase 2 | Status: RECRUITING